Wir sind mit live! Mehr erfahren

Solventum

SOLV

Börsenwert 14,6 Mrd. $

85,81 USD

-2,05

2,33 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

85,81

0,00

0 %

1 Tag

-2,33 %

5 Tage

-1,37 %

1 Monat

-3,4 %

3 Monate

5,03 %

6 Monate

24,58 %

Seit Jahresbeginn

8,59 %

1 Jahr

20,11 %

5 Jahre

7,26 %

10 Jahre

7,26 %

Profil: In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.

Mitarbeiter: 20.000

Gesundheitswesen Medizinische Geräte und Verbrauchsmaterialien

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 66,7 %

Neutral 30 %

Negativ 3,3 %

Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026

EAGAN, Minn., Oct. 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2026 financial results on Thursday, November 5, 2026, after the U.S. financial markets close.

Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026

Zacks Investment Research

Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?

Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?

Zacks Investment Research

Why Solventum (SOLV) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Solventum (SOLV) is a Top Value Stock for the Long-Term

Stock Picks From Seeking Alpha's September 2026 New Analysts

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.

Stock Picks From Seeking Alpha's September 2026 New Analysts

Zacks Investment Research

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play

Solventum trades at a significant discount to medical technology peers, with a forward P/E of ~13x and suppressed EV/EBITDA multiples. Management is executing a portfolio optimization, including a potential spin-off of the Health Information Systems segment to unlock value and reduce debt. Raised 2026 EPS guidance to $7.10-$7.20 and operating margins to 22.2%-22.7%, signaling margin expansion and improved free cash flow allocation.

Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play

Zacks Investment Research

Here's Why You Should Hold Solventum Stock in Your Portfolio for Now

SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.

Here's Why You Should Hold Solventum Stock in Your Portfolio for Now

Zacks Investment Research

Here's Why Solventum (SOLV) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Solventum (SOLV) is a Strong Value Stock

Zacks Investment Research

Why Solventum (SOLV) is a Top Stock for the Long-Term

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Why Solventum (SOLV) is a Top Stock for the Long-Term

Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt